Eli Lilly has agreed to acquire cardiovascular disease treatment specialist Verve Therapeutics in a deal potentially rising ...

FacebookTweetPin The prospects of a ceasefire in the Middle East have dimmed after a series of comments by President Donald [ ...

Verve is developing drug candidates for heart disease, including the PCSK9-targeted VERVE-102, a base-editing therapy.

Wall Street’s main indexes slipped on Tuesday as the Israel-Iran conflict entered its fifth day, denting global investor ...

U.S. stocks are drifting lower, while oil prices are rising again. The S&P 500 fell 0.3% Tuesday. The Dow Jones Industrial ...

Solar stocks drop sharply as Senate Republicans detail changes to Trump’s tax-and-spending bill that would phase out solar, ...

S&P 500 dips on weak retail sales and Iran conflict fears. Will the Fed’s rate decision and rising oil prices drive more volatility this week?

Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Verve Therapeutics, Inc. (NASDAQ: VERV) to Eli Lilly and Company is fair to Verve shareholders. Under the terms of ...

Yum Brands named Chief Financial Officer Chris Turner as its next chief executive. Eli Lilly to Acquire Verve Therapeutics for Up to $1.3 Billion Deal would add a potential treatment for ...

Trading legend Tom Gentile—who’s trained over 300,000 investors—goes live June 18 at 6 PM ET to reveal the market’s hidden ...

Verve's leading programs aim to deliver lifelong cardiovascular risk reduction with a single dose by targeting genes strongly linked to cardiovascular diseaseLilly's established capabilities ...

Bloomberg journalists discuss today's biggest winners and losers in the stock market. Listen for analysis on the companies ...